MedPath

Fexofenadine

Generic Name
Fexofenadine
Brand Names
Allegra, Allegra-D, Mucinex Non-drowsy Allergy, Wal-fex, Telfast
Drug Type
Small Molecule
Chemical Formula
C32H39NO4
CAS Number
83799-24-0
Unique Ingredient Identifier
E6582LOH6V
Background

Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of terfenadine and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.

Indication

In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.

Associated Conditions
Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Seasonal Allergic Rhinitis
Associated Therapies
Antihistamine

Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare

Phase 4
Terminated
Conditions
Gout Flare
Interventions
Drug: Colchicine,
Drug: midazolam,
First Posted Date
2019-05-01
Last Posted Date
2024-06-03
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
26
Registration Number
NCT03933007
Locations
🇫🇷

Hôpital Lariboisière-Service de Rhumatolologie, Paris, France

Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants

Phase 3
Completed
Conditions
Rhinitis Seasonal
Interventions
First Posted Date
2018-09-11
Last Posted Date
2022-04-25
Lead Sponsor
Sanofi
Target Recruit Count
240
Registration Number
NCT03664882
Locations
🇨🇦

Investigational Site Number, Canada, Canada

Fexofenadine Use in Gastroesophageal Reflux Symptoms

Phase 2
Terminated
Conditions
Gastroesophageal Reflux
Interventions
Drug: Placebo - Cap
First Posted Date
2018-02-07
Last Posted Date
2021-02-17
Lead Sponsor
Stanford University
Target Recruit Count
11
Registration Number
NCT03425097
Locations
🇺🇸

Stanford Health Care, Redwood City, California, United States

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001

Phase 1
Conditions
Veisalgia
Interventions
First Posted Date
2017-06-12
Last Posted Date
2017-06-12
Lead Sponsor
Sen-Jam Pharmaceutical
Target Recruit Count
48
Registration Number
NCT03183297

A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants

First Posted Date
2017-04-11
Last Posted Date
2021-06-24
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
35
Registration Number
NCT03108274
Locations
🇳🇿

Clinical Trial Site, Auckland, New Zealand

The Effect Dialysis on the Pharmacokinetics of Fexofenadine

Phase 4
Conditions
Hemodialysis
Interventions
First Posted Date
2017-03-13
Last Posted Date
2017-11-27
Lead Sponsor
Lawson Health Research Institute
Target Recruit Count
30
Registration Number
NCT03078777
Locations
🇨🇦

London Health Sciences Centre, London, Ontario, Canada

Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums

Phase 1
Completed
Conditions
Administration, Oral
Pharmacokinetics
Magnetic Resonance Imaging
Interventions
Device: non-caloric water
Device: caloric drink
Device: grapefruit juice
First Posted Date
2017-01-06
Last Posted Date
2017-01-06
Lead Sponsor
University Medicine Greifswald
Target Recruit Count
9
Registration Number
NCT03012763

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Phase 1
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Osimertininb tablet dosing
First Posted Date
2016-09-21
Last Posted Date
2022-11-14
Lead Sponsor
AstraZeneca
Target Recruit Count
24
Registration Number
NCT02908750
Locations
🇪🇸

Research Site, Sevilla, Spain

Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis

Phase 4
Completed
Conditions
Allergic Rhinitis
Interventions
First Posted Date
2015-09-16
Last Posted Date
2015-09-16
Lead Sponsor
Indira Gandhi Medical College, Shimla
Target Recruit Count
70
Registration Number
NCT02551536

Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail

Phase 1
Completed
Conditions
Drug Interaction
Interventions
Drug: Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam
First Posted Date
2015-03-18
Last Posted Date
2017-02-07
Lead Sponsor
Jules Desmeules
Target Recruit Count
30
Registration Number
NCT02391688
Locations
🇨🇭

Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4, Genève, Switzerland

© Copyright 2025. All Rights Reserved by MedPath